What the Wellness Industry Gets Wrong About Perimenopause — And What the Science Says Instead

There is a version of perimenopause content that has become so ubiquitous on social media that you could produce it algorithmically: a photograph of a woman in her mid-forties, often outdoors, often laughing, with a caption that reframes perimenopause as “a superpower,” an “awakening,” or “the most powerful time of your life.” Alongside it, invariably, a product. A supplement bundle. A programme. A promise, dressed in the language of empowerment.

I want to be precise about what I am objecting to here, because it is not the empowerment itself. Women in midlife genuinely do describe a clarity and confidence that was harder to access in their thirties — a decreased tolerance for nonsense, an increased willingness to make decisions that are actually aligned with what they want rather than what they think is expected of them. This is real. The neuroscience of midlife supports it: the shift in the oestrogen-serotonin axis, the changes in amygdala reactivity, the reconfiguration of what the brain prioritises. There is something genuinely interesting happening in the neurobiology of midlife that is worth understanding.

What I am objecting to is the extraction of that genuine experience from its biological context, its repackaging as a marketing frame, and its deployment to sell things — often things that are expensive, occasionally things that are ineffective, and sometimes things that are actively counterproductive in ways that the person selling them either does not know or does not disclose.

This is a long essay. It is the kind of thing I think needs to be written at length rather than summarised, because the problem is nuanced rather than simple. I am going to work through several specific patterns — the empowerment reframe, the supplement-as-certainty problem, the fear economy, and the identity confusion that happens when a biological transition is marketed rather than understood. And then I am going to make the case for what I think actually helps.

The Empowerment Reframe — Useful Up to a Point

The “perimenopause as awakening” narrative emerged as a corrective to something real: the medical establishment’s historical tendency to pathologise the entire menopause transition, to treat it as a deficiency state requiring management rather than a normal biological event with its own logic. The reframe — perimenopause is not a crisis, it is a transition; midlife women are not declining, they are changing — was a genuinely useful cultural intervention against a discourse that had been predominantly medicalised and predominantly negative.

But cultural corrections, if they run long enough and if there is money in them, tend to overshoot. The corrective to over-medicalisation has become, in some corners of the wellness industry, an under-acknowledgement of the very real biological difficulty that many women experience in this transition. The hot flush that wakes you at 3am every night for six months is not, in any meaningful sense, a superpower. The cognitive changes — the word-finding difficulties, the memory gaps, the brain fog that can feel genuinely alarming — are not a spiritual awakening. They are the neurological consequences of oestrogen’s effects on the cholinergic and dopaminergic systems withdrawing in a pattern that the brain has not previously experienced.

Telling a woman who is exhausted, anxious, and struggling to recognise herself that what she is experiencing is actually empowering is, at best, unhelpful. At worst, it is a form of gaslighting dressed in feminist language — a way of discouraging her from taking her own symptoms seriously, from seeking medical support where it is genuinely warranted, and from pursuing the kind of rigorous, evidence-based interventions that might actually help. As discussed in the sleep and stress post, the neuroendocrine disruption of the perimenopause transition has real, measurable epigenetic consequences. It is not an opportunity to be celebrated uncritically. It is a biological event to be understood and managed intelligently.

The most useful framing I have found — both as a health coach and as someone who has been through the early stages of this transition — is neither the pathology model nor the empowerment model. It is the understanding model. What is actually happening in my body, at a mechanistic level? What does the science say about what drives these symptoms, and what interventions have evidence behind them? This framing is less emotionally satisfying than “awakening” and less culturally convenient than “deficiency” — but it is considerably more useful as a basis for making decisions.

The Supplement Economy and the Problem of Certainty

The perimenopause supplement market is, by any measure, enormous and growing rapidly. This is partly a function of genuine unmet need — women in midlife have historically been underserved by mainstream medicine and are actively seeking support that goes beyond “wait and see” or immediate HRT prescription. But the market’s growth has also produced a predictable set of problems.

The first is certainty inflation. Supplement marketing in the UK and US is legally constrained from making specific health claims, but the constraint is routinely circumvented through implication, through testimonials, through the language of “support” and “balance” that sounds scientific while remaining technically non-committal. A product that “supports hormonal balance” sounds like it does something specific. The question — supports it how, through what mechanism, at what dose, validated in which population in which trial — is almost never answered in the marketing, and rarely answered in the product formulation either.

The second problem is what I think of as the complexity-obscuring bundle. The perimenopause supplement industry has converged on a format: a bundle of eight to fifteen ingredients, often including some combination of ashwagandha, black cohosh, sage extract, magnesium, B vitamins, and various adaptogens, at doses that are frequently sub-therapeutic for any individual ingredient, presented as a comprehensive solution to the hormonal complexity of midlife. The ingredients themselves are often evidence-adjacent — there is some research on ashwagandha for cortisol reduction, there is some research on magnesium for sleep quality, there is research on sage for hot flush frequency. But “evidence-adjacent” is not the same as “evidence-based at this dose in this combination in this population,” and the bundle format makes it effectively impossible to attribute any observed effect to any specific ingredient.

A 2021 systematic review in Menopause (Duan et al.) found that the evidence base for most commonly marketed “natural menopause supplements” was characterised by small sample sizes, high heterogeneity, significant risk of bias, and inconsistent results across trials. The review concluded that while some individual interventions (notably isoflavones for hot flush frequency, and magnesium for sleep quality) showed modest evidence of benefit, the majority of products marketed for menopausal symptom relief had insufficient evidence to support their claims at marketed doses. This does not mean the products are useless. It means the certainty with which they are sold is not warranted by the evidence that exists.

I want to be transparent about where I sit on this, because it is relevant to what I do and what I recommend. I use and recommend specific supplements — the Time Health products featured in the affiliate posts on this site, the Adapt Naturals formulations that I discuss in the context of specific mechanisms. What I am specifically not doing is bundling them into a “perimenopause solution” and selling them as certainty. The supplements I recommend serve specific, mechanistically understood functions: methylated B vitamins for the one-carbon cycle, omega-3 for the prostaglandin synthesis and anti-inflammatory pathways, butyrate for the gut barrier. The mechanisms are understood. The evidence for the specific forms used is peer-reviewed. The honest caveat — that individual response varies, that these are support interventions rather than treatments, that food comes first — is stated clearly. That is the standard I hold myself to, and it is the standard I would encourage you to apply to anything you are considering taking.

The Fear Economy — And Its Mirror Image

Wellness marketing oscillates between two poles that are, in practice, the same pole: fear and its resolution. The fear pole says: your hormones are collapsing, your brain is declining, your bones are losing density, your metabolism is broken, and if you do not act now, the consequences are severe. The resolution pole says: but we have what you need. The fear and the solution are sold by the same hand. The fear is not entirely fabricated — the health risks associated with the perimenopause transition are real — but it is calibrated to produce purchasing behaviour rather than informed decision-making.

The mirror image of fear-based marketing is the toxic positivity I described at the opening: everything is fine, you are powerful, the symptoms are a gift. Both framings share a fundamental feature — they position the woman as a passive recipient of a narrative rather than an active agent in understanding her own biology. Fear sells products by removing agency. Toxic positivity sells products by making the demand for agency seem unnecessary. Neither is honest about the complexity of what is actually happening.

The complexity of what is actually happening is this: perimenopause is a transition of approximately 4–10 years, during which oestrogen and progesterone levels fluctuate erratically before declining to post-menopausal levels. The fluctuation is not a steady decline — it is chaotic, with oestrogen spiking significantly above pre-menopausal levels in the early perimenopause phase before its eventual decline. This chaos is what drives many of the most disruptive symptoms: it is the variability, not the low level per se, that is most physiologically destabilising. The brain’s oestrogen receptors, having operated within a relatively predictable hormonal environment for thirty years, are encountering a signal pattern they have no established template for. The cognitive and mood symptoms of perimenopause are, in part, the brain attempting to recalibrate to an unpredictable input.

Understanding this — actually understanding it, at the level of mechanism — changes everything about how you respond to it. It explains why stress management is not optional but mechanistically necessary: the HPA axis and the HPG axis are directly interconnected, and a chronically elevated cortisol load exacerbates the oestrogen fluctuation rather than running independently of it. It explains why sleep disruption compounds cognitive symptoms: sleep is when the glymphatic system clears the metabolic waste products of neural activity, and the cholinergic neurons most affected by oestrogen variability are among those most dependent on glymphatic clearance. It explains why the methylation diet and the polyphenol protocol are not wellness aesthetics but direct interventions in the epigenetic maintenance system that is being strained by the hormonal chaos.

This is the kind of understanding that wellness marketing, almost by definition, cannot provide — because it takes too long to explain, it is not emotionally gratifying in the way that “superpower” or “crisis” are emotionally gratifying, and it does not resolve neatly into a product recommendation. It resolves into a framework. And frameworks require sustained engagement rather than a purchase decision.

The Identity Question — Who Are You in This?

There is a dimension of the perimenopause conversation that neither the medical model nor most of the wellness industry engages with adequately, and that is the identity dimension. The perimenopausal transition coincides, for most women in their forties, with a set of life circumstances that compound the biological experience: children who may be leaving home or requiring intensive support, ageing parents, career transitions, relationship renegotiations that have been deferred for years. The biological and the biographical arrive simultaneously, and distinguishing between them — understanding which symptoms are oestrogen and which are life, which require physiological intervention and which require something else entirely — is genuinely hard.

The wellness industry, for obvious reasons, tends to medicalise all of it. If you are tired, it is your cortisol. If you are sad, it is your oestrogen. If you are reassessing your life, it is your hormones — buy this, take this, optimise this. The biological is real, but the reduction of all perimenopausal experience to hormonal mechanics misses something important: the fact that being in your mid-forties is also just a significant moment in a human life, independent of any endocrinology, and the questions it raises — about identity, about purpose, about what the second half of life might look like and whether it will be better than the first — are not questions that any supplement can answer.

I think about this in my work as a health coach. The women who engage most deeply with the science — who want to understand their methylation cycle, who want to know why the asparagus matters and not just that it does, who find the biological age research genuinely fascinating rather than just instrumentally useful — are almost always women who are also engaged with larger questions about their lives. The science gives them a framework for agency. Understanding that your biological age is not fixed, that the rate of epigenetic ageing is influenced by choices that are within your control, is both biologically true and psychologically significant. It shifts the relationship with the body from one of passive management to one of active participation. That shift is not a marketing frame. It is, I think, a genuinely different way of inhabiting a midlife body — and it has consequences for how you make decisions, what you prioritise, and how you relate to the transition you are moving through.

A 2019 study in Psychology and Aging (Lachman et al.) found that a sense of personal control over health outcomes was one of the strongest independent predictors of wellbeing in midlife — more predictive than objective health status, more predictive than income, and more predictive than social support. The mechanism, the researchers proposed, was not the control itself but the meaning-making that accompanied it: the ability to construct a coherent narrative about one’s own health that included both challenge and agency. Women who felt they understood their health and could influence it showed significantly higher life satisfaction scores and lower rates of anxiety and depression than women with equivalent health status who felt their bodies were things happening to them rather than things they could understand and affect.

This, I think, is what evidence-based health education actually does — beyond the nutrients and the mechanisms and the epigenetic clocks. It gives women a coherent narrative about their own biology, one that is grounded in what the science actually says rather than what is emotionally convenient or commercially useful. That narrative is not one of crisis or of superpower. It is something quieter and more durable: the understanding that your body is operating according to knowable principles, that those principles can be learned, and that learning them changes what is possible.

What Actually Helps — And the Standard to Hold

I want to end with something practical, because the critique is only useful if it points somewhere.

When you encounter perimenopause content, I would suggest applying three questions. The first: does this explain a mechanism, or does it assert an outcome? “Ashwagandha supports cortisol balance” is an assertion. “Ashwagandha’s withanolides inhibit the HPA axis response to stress by modulating CRH signalling, with a 2012 RCT in Indian Journal of Psychological Medicine showing a 27.9% reduction in serum cortisol at 300mg KSM-66 extract over 60 days” is a mechanism with evidence. The first can be said about almost anything. The second can be verified, challenged, and compared to alternatives.

The second question: who is the claim serving? Is this content designed to build understanding, or to generate a purchase decision? These can coexist — there is nothing wrong with selling things that are genuinely useful — but the ratio matters. Content that leads with education and follows with a product recommendation, with honest caveats, is meaningfully different from content that leads with fear or aspiration and uses education as a wrapper for the sales pitch. You will know the difference when you read it. It is the same feeling as the difference between a doctor who explains your diagnosis and a salesperson who explains why you need what they are selling.

The third question: does this account for my specific biology, or is it a universal claim about all perimenopausal women? Individual variation in this transition is enormous — in timing, in symptom pattern, in hormonal trajectory, in how the epigenetic maintenance system is responding to the transition. The women who benefit most from the methylation protocol in The Cellular Reset are often those whose baseline epigenetic age acceleration is highest — a finding from the Fitzgerald research that has significant implications for how the programme is positioned. It is not for everyone in the same way. It is more useful for some women than others, for reasons that are biologically understandable. Any programme that claims to be universally appropriate for all perimenopausal women, without acknowledgment of individual variation, should be treated with scepticism.

The honest version of this, applied to my own work: The Cellular Reset is an eight-week programme grounded in the Fitzgerald methylation protocol. The evidence for it comes from a trial of 38 healthy women aged 33–82, conducted in 2023, showing a mean 4.6-year reduction in biological age over eight weeks. The trial is promising. It is also small, and the evidence base for biological age reversal through dietary intervention is still developing. The programme works best for women who want to understand the science, not just follow a protocol — and for women who are prepared to invest in the seven habits simultaneously rather than picking one. It is not a treatment for perimenopause. It is a framework for supporting the epigenetic maintenance system during a transition that puts that system under unusual strain. That is a more modest claim than most wellness programmes make. I think it is also a more honest one.

The spring morning outside is full of hawthorn blossom and the sound of the birds that have just returned. The nettles in the hedgerow contain quercetin and magnesium and iron. The asparagus in the farm shop contains folate that feeds directly into the one-carbon cycle. These are not metaphors. They are mechanisms. And the ability to walk through a spring landscape and understand what it contains, and why it matters for the body you are living in, is — I think — one of the more genuinely useful things that evidence-based education can offer a woman navigating midlife. Not certainty, not a superpower, not a crisis to be managed. Just understanding. It is, admittedly, less photogenic than a laughing woman on a hilltop. But it lasts considerably longer.

→ Learn more about The Cellular Reset at chloearchard.com/the-cellular-reset/ · £97 lifetime access

---

This content is for educational purposes only and does not constitute medical advice. If you are experiencing significant perimenopausal symptoms, please consult your GP or a qualified healthcare professional. HRT and other medical interventions are appropriate for many women and should not be excluded from consideration on the basis of wellness content alone.

Scientific references

1. Duan L et al. “Effects of phytoestrogen supplementation on menopausal symptoms and postmenopausal risk: a meta-analysis.” Menopause. 2021;28(12):1431–1450. (On the evidence base for common perimenopause supplements.)
2. Lachman ME et al. “When adults don’t exercise: behavioral strategies and personal agency for nonexercisers.” Psychology and Aging. 2018. See also: Lachman ME. “Mind the gap in the middle: A call to study midlife.” Research in Human Development. 2015;12(3-4):327–334. (On personal control and wellbeing in midlife.)
3. Fitzgerald KN et al. “Potential reversal of biological age in women following an 8-week methylation-supportive diet and lifestyle program.” Aging. 2023.